IP Library Granted Patent US 9,433,646
Granted Patent B2
US 9,433,646 · App. 13/688,864 · Granted Sep 6, 2016

Methods of inhibiting growth of a neoplastic cell

Inventor: Thomas E. Ichim (San Diego, CA)
Assignee: XON CELLS, INC.
A61K35/50A61K35/44C12N5/0605
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,433,646
App. No.
13/688,864
Granted
Sep 6, 2016
Kind
B2
Abstract

Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.

Claims (13)

1. A method of inhibiting growth of a neoplastic cell, the method comprising:

(a) providing a cell free-placental extract made by the process comprising:

(i) obtaining human placenta;

(ii) homogenizing the obtained human placenta by digesting the obtained human placenta with a collagenase and a heparitinase, wherein the heparitinase digestion is at a neutral pH, the homogenization resulting in a homogenate;

(iii) centrifuging said homogenate to produce a supernatant free of cellular debris; and

(iv) purifying the supernatant to obtain cell free-placental extract comprising a cell differentiation-inducing fraction having a molecular weight in the range from about 10 Daltons to about 10,000 Daltons

(b) directly administering said cell free-placental extract to the neoplastic cell which is selected from the group consisting of a leukemia cell, and a prostate cancer cell, thereby inhibiting growth of the neoplastic cell.

2. The method of claim 1 , wherein the step (iv) of purifying comprises running the supernatant through adsorption on a C-18 column, and then filter sterilizing the purified supernatant.

3. The method of claim 1 , wherein the neoplastic cell is in vivo.

4. The method of claim 1 , wherein the neoplastic cell is in vitro.

5. The method of claim 1 , wherein the administered cell free-placental extract is in a liposomal complex.

6. The method of claim 1 , wherein a histone deacetylase inhibitor is added to the extract prior to the administration of said cell free placenta.

7. The method of claim 1 , wherein the step(ii) further comprises sonicating the the homogenate.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded May 16, 2016
From: MEDISTEM INC.; XON CELLS, INC.
To: XON CELLS, INC.
Reel/Frame 038711/0317 →
CHANGE OF NAME Recorded Nov 22, 2013
From: MEDISTEM LABORATORIES, INC.
To: MEDISTEM INC.
Reel/Frame 031655/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2013
From: ICHIM, THOMAS E.
To: MEDISTEM LABORATORIES, INC.
Reel/Frame 031649/0470 →
Continuity (4)
Continuation 12955755 · Nov 29, 2010
Continuation 11486635 · Jul 13, 2006
Provisional Application 60699579 · Jul 14, 2005
Related Publication 20130156847A1 · Jun 20, 2013